Nivolumab provides improved effectiveness and safety compared with docetaxel as a second ‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

ConclusionsFor advanced NSCLC, nivolumab is a better therapy in terms of both anti ‐tumor efficacy and safety than docetaxel‐based chemotherapy. More high‐quality randomized controlled trials are needed to confirm these results.

Source: Cancer Medicine - January 9, 2019 Category: Cancer & Oncology Authors: Zheng Xu, Fengming Yi, Dongliang Yu, Jianjun Xu, Yiping Wei, Wenxiong Zhang Tags: ORIGINAL RESEARCH Source Type: research